GRAIL, Inc. (NASDAQ: GRAL) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit

National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against GRAIL, Inc. (NASDAQ: GRAL ) ("GRAIL" or the "Company") on behalf of investors who purchased or acquired GRAIL common stock during the period from May 13, 2025 through February 19, 2026 (the "Class Period"). Investor Deadline: Investors who purchased or acquired GRAIL common stock during the Class Period may, no later than August 4, 2026 , seek to be appointed as a lead plaintiff representative of the class. The complaint alleges that Defendants failed to disclose that: (i) the NHS-Galleri trial, as structured and executed within its three-year follow-up period, was insufficient to demonstrate whether GRAIL's primary endpoint — a statistically significant reduction in Stage III-IV cancers — was achievable; and (ii) Defendants repeatedly declined to share detailed top-line data or other results from the trial that may have revealed adverse trends, including the possibility that a materially longer timeline or different study design would be necessary. On February 19, 2026, GRAIL disclosed that the trial's primary endpoint had not been met. The Company acknowledged that a longer follow-up period would likely be needed to draw adequate comparisons between study arms. On this news, shares of GRAIL common stock fell from a close of $101.53 per share to a close of $50.21 per share, a decline of approximately 50.55% in a single trading day.